n added: "I am pleased and honored to be joining the Board of
Directors of Transdel Pharmaceuticals and look forward to contributing to the
company's future success. Transdel's transdermal delivery platform technology
is truly impressive. Given the growth of sports medicine, I am particularly
excited about the company's lead drug, Ketotransdel(TM), its topical NSAID
cream formulation for pain management and the unmet medical need that it will
potentially fulfill."
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (OTCBB: TDLP - News) is a specialty
pharmaceutical company developing non-invasive, topically delivered
medications. The Company's innovative patented proprietary Transdel(TM) cream
formulation technology is designed to facilitate the effective penetration of
drugs through the tough skin barrier to reach the target underlying tissues.
In the case of Ketotransdel(TM), the Transdel(TM) cream allows the active
ingredient ketoprofen to reach the target soft tissue and exert its well-known
anti-inflammatory and analgesic effects. The Company is also investigating
other drug candidates and treatments for transdermal delivery using the
patented Transdel(TM) platform technology for products in pain management and
other therapeutic areas. For more information, please visit
http://www.transdelpharma.com.
Safe Harbor Statement
The statements which are not historical facts contained in this press
release are forward-looking statements that involve certain risks and
uncertainties including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements,
development of new products, government approval processes, the impact of
competitive products or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed in the Company'
'/>"/>
SOURCE Transdel Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine news :1.
Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference2.
Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections3.
Alseres Pharmaceuticals, Inc. Announces $1 Million Financing4.
Keryx Biopharmaceuticals Receives Nasdaq Notification5.
Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neuropathic Pain6.
FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date7.
Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference8.
MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results9.
MAP Pharmaceuticals Reports Third Quarter of 2008 Financial Results10.
Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit11.
Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts